Keytruda qlex 395 MG-4800 unit 2.4ML

Ended Awarded

Contract number
SPE2DR26FHPQ1
Awardee
Awarding agency
Obligated
$8,468

Award facts

Contract value 100% obligated
$8,468.28 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
424210 Drugs and Druggists' Sundries Merchant Wholesalers
PSC
6505 Drugs And Biologicals
Set-aside
No set-aside
Competition
Full and Open Competition Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Park Ridge, IL 60068, USA

Award details come from SAM.gov/FPDS.

About this award

The Defense Logistics Agency issued a $8,468.28 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business, on July 8, 2026, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for Keytruda (pembrolizumab) 395 mg, 4,800 unit, 2.4 mL formulation.

PPV-G GEN V is the Defense Logistics Agency's single-award indefinite delivery contract framework for branded and generic pharmaceuticals, biologics, vaccines, and medical consumables supporting Department of Defense military healthcare facilities worldwide. Place of performance is Park Ridge, Illinois. Ultimate completion date for this order is July 29, 2026.

Quick answers

Who was awarded contract SPE2DR26FHPQ1?

SPE2DR26FHPQ1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on July 8, 2026.

How much is contract SPE2DR26FHPQ1 worth?

The government has obligated $8,468 on SPE2DR26FHPQ1.

Is contract SPE2DR26FHPQ1 an order under another contract?

Yes. SPE2DR26FHPQ1 is a delivery order under SPE2DR25D9231, an indefinite delivery contract.

Was contract SPE2DR26FHPQ1 competed?

The extent of competition for SPE2DR26FHPQ1 was full and open competition.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award